EXEL News and Press, Exelixis Inc. From 01/26/23

Credit Suisse has initiated Exelixis ( NASDAQ: EXEL ) with an outperform rating saying that its core medicine, Cabometyx (cabozantinib) is ma market leader and has growth potential with its pipeline. The firm has a $29 price target (67% upside based on Wednesday's close). Analyst ...

– Conference Call and Webcast to Follow at 5: 00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 7, 2023 after the markets close. At 5:00 p...

Update 8:15pm: Adds Exelixis comment. Exelixis ( NASDAQ: EXEL ) had a mixed ruling in its Cabometyx patent trial versus MSN Laboratories. Exelixis rose 2.8% in after hours trading. The judge in the patent case ruled that the 776 patent, which goes to October 2030, wasn'...

Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) v. MSN Laboratories Private Limited et al. ( MSN ), Action No. 19-2017 (Consolidated), the U.S. District Court for the District of Delaware ruled in Exelixis’ favor, rejecting MSN’s...

Exelixis ( NASDAQ: EXEL ) had a mixed ruling in its Cabometyx patent trial versus MSN Laboratories. Exelixis rose 1% in after hours trading. The judge in the patent case ruled that the 776 patent, which goes to October 2030, wasn't infringed, a defeat for Exelixis. ...

The following slide deck was published by Exelixis, Inc. in conjunction with this event. For further details see: Exelixis (EXEL) Presents at 41st Annual Healthcare Conference -Slideshow

Summary Exelixis' CABOMETYX is hitting on all cylinders. Exelixis has an interesting and highly cabozantinib-centric pipeline. Pharma BD is a tricky process that will play a big role in Exelixis' future. This is my first look at Exelixis ( EXEL ). It is a young commerc...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they’re seemingly one news...

Exelixis ( NASDAQ: EXEL ) expects revenue for the fourth quarter to be $415M vs. consensus at $415.86M. For 2022, the company sees revenue of $1.6B vs. consensus at $1.6B. The company also said it expects 2023 revenue of $1.775B-$1.875B vs. consensus at $1.83B. Cabozantinib fr...

– Cabozantinib franchise achieves approximately $1.4 billion in preliminary U.S. net product revenues for full year 2022, including approximately $375 million for fourth quarter 2022 – – Full year 2023 net product revenues guidance of $1,575 millio...